VR Adviser’s Avadel Pharmaceuticals AVDL Stock Holding History

VR Adviser’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,057,827	Closed	-$8.55M	–	24
2020 Q2	$8.55M	Hold	1,057,827	–	–	2.05%	13
2020 Q1	$8.4M	Buy	+1,057,827	New	+$8.13M	2.28%	13

Other funds holding AVDL

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Renaissance Technologies

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

VR Adviser's AVDL Position: Q3 2020 in Review

VR Adviser sold out of Avadel Pharmaceuticals (AVDL) in Q3 2020, closing a stake of 1,057,827 shares — an estimated $8.55M sold.

VR Adviser first reported a position in AVDL in Q1 2020 and held it in 2 quarters. The position peaked at $8.55M in Q2 2020. 79 funds tracked by Wall St. Rank hold AVDL as of Q3 2020.

VR Adviser reported no remaining Avadel Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
VR Adviser sold 1,057,827 Avadel Pharmaceuticals shares in Q3 2020, an estimated $8.55M.
VR Adviser first reported a position in Avadel Pharmaceuticals in Q1 2020 and held it in 2 quarters.
VR Adviser's Avadel Pharmaceuticals position peaked at $8.55M in Q2 2020.
79 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2020.

Based on VR Adviser's 13F filing for Q3 2020, filed 16 Nov 2020.